A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: Apremilast

Expert Review of Clinical Immunology

Volumn 12, Issue 3, 2016, Pages 237-249

  Chiricozzi, Andrea ^a   Caposiena, Dante ^a   Garofalo, Virginia ^a   Cannizzaro, Maria Vittoria ^a   Chimenti, Sergio ^a   Saraceno, Rosita ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

apremilast; oral drug; otezla; phosphodiesterase inhibitor; Psoriasis; small molecule

Indexed keywords

APREMILAST; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE IV; THALIDOMIDE;

ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG CLEARANCE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEDICAL INFORMATION; METABOLIC CLEARANCE; MULTICENTER STUDY (TOPIC); NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE COURSE; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; ORAL DRUG ADMINISTRATION; PSORIASIS; SIGNAL TRANSDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DISEASE PROGRESSION; HUMANS; MOLECULAR TARGETED THERAPY; PSORIASIS; SIGNAL TRANSDUCTION; THALIDOMIDE;

EID: 84959288597     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2016.1134319     Document Type: Article

References (76)

1. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34:J314-J321.
2. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386 (9997):983-994. DOI:10.1016/S0140-6736(14)61909-7.
3. Ficco HM, Citera G, Cocco JA. Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria. Clin Rheumatol. 2014;33(10):1489-1493.
4. Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol. 2007;25:524-528.
5. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496-509.
6. Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol. 2005;5:699-711.
7. Chiricozzi A, Saraceno R, Chimenti MS, et al. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? Expert Opin Ther Targets. 2014;18(5):513-525.
8. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64 (2):ii30-36.
9. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677-687.
10. Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. Cytokine. 2015;73(2):342-350.
11. Man HW, Schafer P, Wong LM, et al. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem. 2009;52(6):1522-1524.
12. Limaye K. Psoriasis: an overview and update. Nurse Pract. 2015;40(3):23-26.
13. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1-10.
14. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861-867.
15. Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645-648.
16. Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol. 2010;160(4):810-820.
17. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62(1):114-135.
18. Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present and future. Clin Exp Dermatol. 2013;38(6):573-588.
19. Colombo MD, Cassano N, Bellia G, et al. Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. Sci World J. 2013;2013:1-11.
20. Saurat JH. Side effects of systemic retinoids and their clinical management. J Am Acad Dermatol. 1992;27(6 Pt 2):S23-28.
21. Carretero G, Ferrandiz C, Dauden E, et al. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. Eur Acad Dermatol Venereol. 2015;29(1):156-163.
22. Novelli L, Chimenti MS, Chiricozzi A, et al. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies. Autoimmun Rev. 2014;13:64-69.
23. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850.
24. Burden AD, Hilton Boon M, Leman J, et al. Diagnosis and management of psoriasis and psoriatic arthritis in adults: summary of SIGN guidance. BMJ. 2010;341:c5623.
25. Dommasch ED, Troxel AB, Gelfand JM. Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses. J Am Acad Dermatol. 2013;68 (5):863-865.
26. Tzellos T, Kyrgidis A, Trigoni A, et al. Association of ustekinumab and briakinumab with major adverse cardiovascular events: an appraisal of meta-analyses and industry sponsored pooled analyses to date. Dermatoendocrinol. 2012;4(3):320-323.
27. Chiricozzi A. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr. 2014;105(1):9-20.
28. Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73 (3):400-409.
29. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338.
30. Gottlieb AB, Langley RG, Philipp S, et al. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials. J Drugs Dermatol. 2015;14(8):821-833.
31. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-tosevere psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386 (9993):541-551.
32. Aslam A, Griffiths CE. Drug therapies in dermatology. Clin Med. 2014;14(1):47-53.
33. Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol. 2002;138(5):686-688.
34. Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014 Aug 1;4(8). pii: a015354. DOI:10.1101/cshperspect.a015354.
35. Kaminska B, Swiatek-Machado K. Targeting signaling pathways with small molecules to treat autoimmune disorders. Expert Rev Clin Immunol. 2008;4:93-112.
36. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583-1590.
37. Kofoed K, Skov L, Zachariae C. New drugs and treatment targets in psoriasis. Acta Derm Venereol. 2015 Feb;95 (2):133-139.
38. Hansen RB, Kavanaugh A. Novel treatments with small molecules in psoriatic arthritis. Curr Rheumatol Rep. 2014;16:443.
39. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109 (3):366-398.
40. Ahmad F, Murata T, Shimizu K, et al. Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. Oral Dis. 2015;21(1):e25-50.
41. Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cellular Signalling. 2014;26:2016-2029.
42. Pfeifer A, Kili A, Hoffmann LS. Regulation of metabolism by cGMP. Pharmacol Ther. 2013;140(1):81-91.
43. Azevedo MF, Faucz FR, Bimpaki E, et al. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev. 2014;35(2):195-233.
44. Abdulrahim H, Thistleton S, Adebajo AO, et al. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis. Expert Opin Pharmacother. 2015;16 (7):1099-1108.
45. Mahmood T, Zaghi D, Menter A. Emerging oral drugs for psoriasis. Expert Opin Emerg Drugs. 2015;20 (2):209-220.
46. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates antiinflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842-855.
47. Claveau D, Chen SL, O'Keefe S, et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther. 2004;310:752-760.
48. Conti M, Richter W, Mehats C, et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem. 2003;278:5493-5496.
49. Odingo JO. Inhibitors of PDE4: a review of recent patent literature. Exp Opin Ther Pat. 2005;15:773-787.
50. Calverley PMA, Fabbri LM, Rabe KF, et al. Roflumilast in the treatment of COPD: a pooled safety analysis. Eur Respir J. 2010;36(54):Abstract P4001.
51. Scanlon PD. The pathogenesis and pathology of COPD: identifying risk factors and improving morbidity and mortality. Adv Stud Med. 2004;4(10A):SS744-S749.
52. Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaquetype psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008;24(5):1529-1538.
53. Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013;12(8):888-897.
54. Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016-2029.
55. [cited 2015 Dec 17]. Available from: http://ec.europa.eu/health/documents/community-register/2015/20150115130395/anx-130395-en.pdf
56. Hoffmann M, Kumar G, Schafer P, et al. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. Xenobiotica. 2011;41 (12):1063-1075.
57. Schett G, Sloan VS, Stevens RM, et al. Apremilast: A novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis. 2010;2(5):271-278.
58. Available from: http://www.otezla.com/otezla-prescrib ing-information.pdf
59. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583-1590.
60. Abdulrahim H, Thistleton S, Adebajo AO, et al. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis. Expert Opin Pharmacother. 2015;16 (7):1099-1108.
61. Papp K, Kaufmann R, Thaçi D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013;27(3):e376-383.
62. Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380(9843):738-746.
63. Apremilast: Phase 2,3,4-List Results. Bethesda (MD): US National Library of Medicine. [cited 2015 Aug 7]. Available from: www.ClinicalTrials.gov.
64. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73 (1):37-49.
65. Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015 Sep 10;173:1387-1399. DOI:10.1111/bjd.14164. [Epub ahead of print].
66. Reich K, Papp K, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 1) [oral]. Oral presented at: 71st Annual Meeting of the American Academy of Dermatology (AAD); 2013 Mar 1-5; Miami Beach, FL.
67. Paul C, Cather J, Gooderham M, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2) [poster]. Poster presented at: 72nd Annual Meeting of the American Academy of Dermatology (AAD); 2014 Mar 21-25; Denver, CO.
68. Papp K, Reich K, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from the randomized treatment withdrawal phase of a phase 3, randomized, controlled trial (ESTEEM 1) [poster]. Poster presented at: 72nd Annual Meeting of the American Academy of Dermatology (AAD); 2014 Mar 21-25; Denver, CO.
69. Reich K, Papp K, Leonardi C, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from a phase III, randomized, controlled trial (ESTEEM 1) [poster]. Poster presented at: 72nd Annual Meeting of the American Academy of Dermatology (AAD); 2014 Mar 21-25; Denver, CO.
70. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37-49.
71. Reich K, Sobell J, Day R, et al. Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: pooled analysis of the ESTEEM 1 and ESTEEM 2 trials. Poster 1162. Presented at: the 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20-24; San Francisco, CA.
72. Available from: http://www.otezla.com/wp-content/uploads/2014/05/otezla-prescribing-information.pdf
73. Houslay MD, Schafer P, Zhang K. Phosphodiesterase-4 as a terapeutic target. Drug Discov Today. 2005;10:1503-1519.
74. Feldam SR, Tencer T, Clancy Z, et al. Cost per responder of apremilast versus etanercept, adalimumab, and ustekinumab in patients with moderate to severe psoriasis. Poster 1108. Presented at the 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20-24; San Francisco, CA.
75. Danesh MJ, Beroukhim K, Nguyen C, et al. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis. Dermatol Online J. 2015 Jun 16;21(6). pii: 13030/qt5gf406zs.
76. Liu Y, Zhou S, Nissel J, et al. The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis. Clin Pharmacol Drug Dev. 2014;3 (6):456-465.